IL191356A0 - Therapeutic materials - Google Patents

Therapeutic materials

Info

Publication number
IL191356A0
IL191356A0 IL191356A IL19135608A IL191356A0 IL 191356 A0 IL191356 A0 IL 191356A0 IL 191356 A IL191356 A IL 191356A IL 19135608 A IL19135608 A IL 19135608A IL 191356 A0 IL191356 A0 IL 191356A0
Authority
IL
Israel
Prior art keywords
therapeutic materials
therapeutic
materials
Prior art date
Application number
IL191356A
Other languages
English (en)
Original Assignee
Ariad Gene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Gene Therapeutics Inc filed Critical Ariad Gene Therapeutics Inc
Publication of IL191356A0 publication Critical patent/IL191356A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL191356A 2005-11-14 2008-05-12 Therapeutic materials IL191356A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73676305P 2005-11-14 2005-11-14
PCT/US2006/044146 WO2007059106A2 (en) 2005-11-14 2006-11-14 Administration of mntor inhibitor to treat patients with cancer

Publications (1)

Publication Number Publication Date
IL191356A0 true IL191356A0 (en) 2009-08-03

Family

ID=38049229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191356A IL191356A0 (en) 2005-11-14 2008-05-12 Therapeutic materials

Country Status (9)

Country Link
US (1) US20070185150A1 (OSRAM)
EP (2) EP2662082A1 (OSRAM)
JP (2) JP5709354B2 (OSRAM)
CN (2) CN102579467A (OSRAM)
AU (1) AU2006315512B2 (OSRAM)
CA (1) CA2629714A1 (OSRAM)
EA (1) EA015922B1 (OSRAM)
IL (1) IL191356A0 (OSRAM)
WO (1) WO2007059106A2 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
AU2010236825A1 (en) 2009-04-16 2011-09-15 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
US10485792B2 (en) 2009-08-26 2019-11-26 Hadasit Medical Research Services & Development Limited Sustained release delivery systems for the prevention and treatment of head and neck cancers
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2558092B1 (en) * 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
PH12013502077A1 (en) * 2011-04-25 2013-12-16 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
CN104093398B (zh) * 2011-12-02 2017-03-15 西格诺药品有限公司 7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法
SG10201608469RA (en) * 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP2919759A4 (en) * 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN106166296A (zh) * 2016-07-01 2016-11-30 江南大学 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
US20230346762A1 (en) * 2020-02-21 2023-11-02 Korea Advanced Institute Of Science And Technology Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient
CN114767867A (zh) * 2021-12-22 2022-07-22 中山大学孙逸仙纪念医院 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DK0525960T3 (da) 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
AU686629B2 (en) 1993-04-23 1998-02-12 Wyeth Rapamycin Conjugates and Antibodies
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
ATE198041T1 (de) 1993-09-28 2000-12-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0000482D0 (en) 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
EP2762140B1 (en) 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
NZ540047A (en) * 2001-04-06 2007-01-26 Wyeth Corp Use of combination consisting of rapamycin 42-ester with CCI-779, 5-fluorouracil and/or gemcitabine and optionally leucovorin and/or levofolinate for treating a neoplasm
BR0210112A (pt) 2001-05-30 2004-06-08 Novartis Ag Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
WO2003064383A2 (en) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
CN100415233C (zh) 2002-09-17 2008-09-03 惠氏公司 口服制剂
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
DK1701698T3 (da) 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
US7405497B2 (en) 2004-04-13 2008-07-29 Electrovaya Inc. Integrated power supply system
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method
JP2008530145A (ja) 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
DE102005017313A1 (de) 2005-04-14 2006-10-19 Volkswagen Ag Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug
AR058505A1 (es) * 2005-11-04 2008-02-06 Wyeth Corp Combinaciones antineoplasicas de temsirolimus y malato de sunitinib

Also Published As

Publication number Publication date
CN101360495A (zh) 2009-02-04
AU2006315512A1 (en) 2007-05-24
JP5709354B2 (ja) 2015-04-30
US20070185150A1 (en) 2007-08-09
JP2009515901A (ja) 2009-04-16
CN101360495B (zh) 2012-03-14
EA200801309A1 (ru) 2008-10-30
EP2662082A1 (en) 2013-11-13
AU2006315512B2 (en) 2012-11-01
EA015922B1 (ru) 2011-12-30
CA2629714A1 (en) 2007-05-24
WO2007059106A3 (en) 2008-06-05
CN102579467A (zh) 2012-07-18
EP1962839A2 (en) 2008-09-03
WO2007059106A2 (en) 2007-05-24
JP2014012721A (ja) 2014-01-23
EP1962839A4 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
IL191356A0 (en) Therapeutic materials
GB0518390D0 (en) Therapeutic compounds
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
GB0518237D0 (en) Therapeutic compounds
GB0506147D0 (en) Therapeutic agents
GB0509326D0 (en) Therapeutic compounds
GB0509573D0 (en) Therapeutic compounds
SI1877096T1 (sl) Terapija ledvičnih kamnov brez litotripsije
GB0518361D0 (en) Therapeutic compounds
GB0522881D0 (en) Therapeutic compounds
GB0505437D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
GB0509405D0 (en) Therapeutic compounds
GB0513747D0 (en) Therapeutic compounds
GB0514738D0 (en) Therapeutic agents
GB0516661D0 (en) Therapeutic agents
GB0507003D0 (en) Therapeutic
GB0522130D0 (en) Therapeutic compounds
GB0526107D0 (en) Therapeutic Compounds
GB0518235D0 (en) Therapeutic compounds
GB0518720D0 (en) Therapeutic combination
GB0501655D0 (en) Therapeutic use
GB0515580D0 (en) Therapeutic compounds
GB0510908D0 (en) Therapeutic compounds
GB0510905D0 (en) Therapeutic compounds